ProPharma’s team of dedicated experts is at the forefront of both existing and emerging industry trends. ProPharma’s team inspires tomorrow by leveraging rich data insights across our service lines and functional areas to develop innovative solutions that answer the most complex needs of both existing and prospective clients.
Do You Need an LPPV in the Nordic Countries?
While the Nordic countries are often viewed as a single region, pharmacovigilance (PV) requirements and local expectations can vary from country to country. Understanding where local representation is required, and where it remains optional, is essential for Marketing Authorization Holders (MAHs)...
From Defensible to Predictive: How High-Functioning MLR Teams Are Evolving Their Risk Assessment Approach
For several years, FDA's Office of Prescription Drug Promotion (OPDP) maintained a relatively low enforcement profile. For example, between 2022 and 2024, the Agency issued only 14 Untitled and...
AI-Readiness 101: AI Success Starts with Understanding Your Data
Everyone wants AI. Executives want faster insights. Scientists want to find information more quickly. Operations teams want to reduce manual effort. Technology leaders want to unlock value from years...
What It Takes to Build a Successful Global Medical Information Program in Veterinary Medicine
When animal health companies expand globally, attention typically focuses on product registration, market access, supply chain planning, and commercialization. Medical information is often considered...
Inspection Readiness: From Regulatory Compliance to Sustainable Quality Culture
The Evolving Global Regulatory Landscape As the pharmaceutical industry continues to operate in an increasingly globalized environment, regulatory oversight has evolved into a more interconnected,...
Marketing Authorization in Eastern Europe: Navigating Regulatory Complexity and Market Opportunities
Navigating Market Access in Eastern Europe The role of the Marketing Authorization Holder (MAH) is central to bringing pharmaceutical products to patients in the European Union and associated...
What challenges are we seeing as life sciences organizations expand AI adoption? Artificial intelligence (AI) is increasingly embedded in compliance areas like medical information, pharmacovigilance,...
Digital Transformation First: Why AI Investment Depends on Strategy, Data, and Operational Readiness
Our recent LinkedIn poll asked a simple question: What is the first step in a digital transformation journey? The response was decisive. Seventy percent of respondents identified strategy definition...
Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy
Clinical trials rarely unravel because of one isolated event. Many continue to progress with underlying issues that gradually impact timelines, data quality, and overall study confidence. A missed...
Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an FDA Inspection
FDA's New Quality Management System Regulation Raises the Bar for Inspection Readiness FDA's Quality Management System Regulation (QMSR), which became effective on February 2, 2026, represents one of...
Efficiency and Compliance: Mastering Legal Case Processing in Pharmacovigilance
In the complex landscape of modern pharmacovigilance (PV), the intersection of patient safety and legal litigation poses unique challenges for Marketing Authorization Holders (MAHs). While...
EMA PRIME Eligibility: Accelerating Access to the European Union Market
Developing innovative medicines requires more than scientific excellence. It also requires a regulatory strategy that supports efficient development, aligns with evolving regulatory expectations, and...
From Feasibility to First Patient In: Streamlining Study Start‑Up with Confidence
Clinical trial timelines are rarely lost during study conduct but are lost long before the first patient is screened. Delays in study startup often begin at country selection and feasibility where...
QMSR Explained: Key Changes from FDA QSR to the New Quality Management System Regulation
The FDA's transition from the long-standing Quality System Regulation (QSR, 21 CFR Part 820) to the new Quality Management System Regulation (QMSR) represents one of the most significant regulatory...
Building Relationships with Sites: The Hidden Driver of Faster Start-Ups
Humanized content about engagement strategies with sites and investigators. The Study Start Up (SSU) phase of clinical trials always feels very chaotic when you are in the “thick of it” with...
In about a week, the committee that advises the FDA on pharmacy compounding will hold a public meeting on several peptides that are popular in sports medicine and do-it-yourself physical...
Compiling and submitting a New Drug Application (NDA) submission is a complicated and intensive activity. Once you have submitted your application to FDA, you may be curious about what can you expect...
Safety Data Exchange Agreements (SDEAs) and Pharmacovigilance Agreements (PVAs) – An Overview
A Safety Data Exchange Agreement (SDEA) or Pharmacovigilance Agreement (PVA) is a legal written contract which ensures that all safety data, PV tasks and responsibilities are detailed between two or...
The FDA’s homepage contains an item in the Public Health Focus section from the Office of Communications entitled “Don’t Use Expired Medicine.” Given this mandate, I recall from many years ago the...
An Overview of the PSMF: Pharmacovigilance System Master File
What is a PSMF? The EU Pharmacovigilance System Master File (PSMF) is a legally required document created and maintained by a Marketing Authorisation Holder (MAH). Essentially, the document is a...
The Importance of the eCTD Structure for FDA Approval
The Importance of the eCTD To harmonize the process of regulatory reviews for global drug development, a unified structure was developed and implemented for electronic Common Technical Document...
The term Functional Service Provider (FSP) concept is highly regarded in the field of clinical research. With drug discovery and clinical trials becoming more complex, pharmaceutical firms and...